1) Boylan KR, Bieling PJ, Marriott M, et al:Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry 65:1106-1113, 2004
2) Branchek TA, Blackburn TP:5-HT6 receptors as emerging targets for drug discovery. Ann Rev Pharmacol Toxicol 40:319-334, 2000
3) Keller MB, Lavori PW, Coryell W, et al:Bipolar Ⅰ:A five-year prospective follow-up. J Nerv Ment Dis 181:238-245, 1993
4) 小野久江,田中和芳,西村裕美子,他:精神運動興奮を有する日本人の統合失調症患者にolanzapine速効型筋注製剤を投与した時の薬物動態の検討—Olanzapine速効型筋注製剤第Ib相臨床試験.臨床精神薬理 11:477-489, 2008
5) Simon NM, Otto MW, Wisniewski SR, et al:Anxiety disorder comorbidity in bipolar disorder patients:Data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder(STEP-BD). Am J Psychiatry 161:2222-2229, 2004
6) Stefanski R, Goldberg SR:Serotonin 5-HT2 receptor antagonists-potential in the treatment of psychiatric disorders. CNS Drugs 5:388-409, 1997